Ketamine’s Twofold Impact Helps People Reclaim Control From Chronic Pain And Substance Misuse; Olumuyiwa Bamgbade, Salem Pain Clinic, BC, Canada Ketamine’s Dual Benefit for Pain and Substance Misuse Therapy is Value-based Healthcare” — Olumuyiwa Bamgbade SURREY, BRITISH COLUMBIA, CANADA, March 13, 2026 / EINPresswire.com / -- The substance misuse epidemic hurts families, communities, and health systems across our society. Many people living with chronic pain get trapped in a hard cycle. They hav

MADISON, Wis., March 13, 2026 /PRNewswire/ -- Beginning today, Walgreens customers can access tools and resources to better understand their colorectal cancer screening options — including a streamlined pathway that enables eligible, average-risk patients to request screening with the Cologuard® test. In recognition of Colorectal Cancer Awareness Month and to help remove barriers to screening and support earlier detection of colorectal cancer, when it is most treatable, Walgreens is working to i

Sana Biotechnology shared follow-up data for its islet cell therapy UP421 on Friday, demonstrating that the pancreatic beta cells have continued to survive — and function — 14 months after they were transplanted into a patient with type 1 diabetes. UP421 comprises hypoimmune-modified primary islet cells sourced from a deceased donor. The allogeneic therapy is being studied in an investigator-sponsored trial run in collaboration with Sweden's Uppsala University Hospital; in December 2024, UP421 w

GSK's RSV shot wins broader US labelFDA clears Novartis' Cosentyx for children 12 and up with HSLilly boosts Japan supply hubGSK's RSV shot wins broader US labelGSK said its respiratory syncytial virus (RSV) vaccine Arexvy has secured a new label expansion from the FDA, allowing its use in adults aged 18 to 49 who are at increased risk for RSV-related lower respiratory tract disease.The shot was first cleared in 2023 for adults aged 60 and older, and later broadened for those aged 50 to 59 with

Shares in Immutep cratered as much as 88% on Friday after the company announced that a Phase III study of eftilagimod alfa — a soluble LAG-3 protein and MHC Class II agonist — for first-line treatment of non–small-cell lung cancer (NSCLC) will be halted due to futility. "We are very disappointed and surprised with the outcome…in light of [eftilagimod alfa's] performance in every other clinical trial," said CEO Marc Voigt.The TACTI-004 study, whose dual primary endpoints were progression-free sur

Australia approves lung cancer AI from the UK Australia's Therapeutic Goods Administration has recently granted approval for an AI-powered lung cancer detection platform developed by the United Kingdom-based Optellum. The Virtual Nodule Clinic platform incorporates a clinically validated lung cancer prediction AI tool used for nodule risk stratification and care pathway prioritisation. The software is already cleared or authorised for clinical use in the United States, the European Union and the

RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $400

In contemporary organic synthesis, particularly in the research and development of peptides and pharmaceutical intermediates, di-tert-butyl dicarbonate (commonly known as Boc anhydride) has long been an indispensable core reagent. As a widely used functional group modifier for amino acid amino protection in recent years, its status as the preferred alternative to traditional chlorocarbonate-based protecting agents stems not only from its exceptional protection efficiency but also from the unprec

Toronto, Ontario--(News - March 13, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces that it has granted incentive stock options to its directors, officers and certain consultants of the Company to purchase up to an aggregate of 2,850,000 common shares of the Company pursuant to its 10% rolling stock option plan. All options are fully ve

————- The following is Part 1 of a two-part series exploring how pharmacogenetic (PGx) testing can help senior living communities navigate medication conversations and support more personalized care. The series is written by Dr. Troy Veale, CEO of PHD Laboratory, a healthcare innovator with more than 25 years of experience in behavioral health and over a decade in laboratory science focused on advancing precision medicine and improving patient outcomes. ————- In senior living, some of the most i